GlpBio

Hippuric acid (2-Benzamidoacetic acid)

目录号: GC33778纯度: >99.00%同义词: 马尿酸,2-Benzamidoacetic acid
Hippuric acid (2-Benzamidoacetic acid) 是一种口服活性代谢物。
Hippuric acid (2-Benzamidoacetic acid)
Cas No.: 495-69-2
规格价格库存数量操作
5g¥446.00现货
1
10mM (in 1mL DMSO)¥491.00现货
1
电话: 400-920-5774Email: sales@glpbio.cn

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

产品描述 Description

Hippuric acid (2-Benzamidoacetic acid) is an orally active metabolite[1]. Hippuric acid can be produced by the metabolism of polyphenols and benzoic acid by gut microbiota[2]. Hippuric acid is usually used in the study of cardiovascular diseases, metabolic diseases, and inflammation/immunology[3][4].

In vitro, treatment of RAW 264.7 cells and primary mouse bone marrow cells with Hippuric acid (60µg/dL; 4-5days) significantly inhibited osteoclastogenesis and osteoclast resorptive activity[5].

In vivo, Hippuric acid (100mg/kg; intraperitoneal injection; five times per week for 10 weeks) significantly increased serum creatinine and blood urea nitrogen levels, promoted renal fibrosis, and disrupted redox homeostasis in a 5/6 nephrectomy rat model of chronic kidney disease[6]. Hippuric acid (150mg/kg/day; p.o.; 7 days) significantly reduced disease activity index (DAI) scores, colon shortening, and histological inflammation scores, increased colon length, and alleviated histopathological damage in the colon of DSS-induced colitis mice[7].

References:
[1] Nativelle C, Picard K, Valentin I, Lhuguenot JC, Chagnon MC. Metabolism of n-butyl benzyl phthalate in the female Wistar rat. Identification of new metabolites. Food Chem Toxicol. 1999;37(8):905-917.
[2] Edwards SJ, Carter S, Nicholson T, et al. (-)-Epicatechin and its colonic metabolite hippuric acid protect against dexamethasone-induced atrophy in skeletal muscle cells. J Nutr Biochem. 2022;110:109150.
[3] Pero RW. Health consequences of catabolic synthesis of hippuric acid in humans. Curr Clin Pharmacol. 2010;5(1):67-73.
[4] Santhakumar AB, Stanley R, Singh I. The ex vivo antiplatelet activation potential of fruit phenolic metabolite hippuric acid. Food Funct. 2015;6(8):2679-2683.
[5] Zhao H, Lazarenko OP, Chen JR. Hippuric acid and 3-(3-hydroxyphenyl) propionic acid inhibit murine osteoclastogenesis through RANKL-RANK independent pathway. J Cell Physiol. 2020;235(1):599-610.
[6] Sun B, Wang X, Liu X, et al. Hippuric Acid Promotes Renal Fibrosis by Disrupting Redox Homeostasis via Facilitation of NRF2-KEAP1-CUL3 Interactions in Chronic Kidney Disease. Antioxidants (Basel). 2020;9(9):783.
[7] Yang Y, Huang S, Liao Y, et al. Hippuric acid alleviates dextran sulfate sodium-induced colitis via suppressing inflammatory activity and modulating gut microbiota. Biochem Biophys Res Commun. 2024;710:149879.

Hippuric acid (2-Benzamidoacetic acid) 是一种口服活性代谢物[1]。Hippuric acid可由肠道微生物代谢多酚和苯甲酸产生[2]。Hippuric acid通常用于心血管疾病、代谢性疾病和炎症/免疫学的研究[3][4]。

体外实验中，用Hippuric acid（60µg/dL；4-5天）处理RAW 264.7细胞和原代小鼠骨髓细胞，显著抑制了破骨细胞生成和破骨细胞的吸收活性[5]。

体内实验中，Hippuric acid（100mg/kg；腹腔注射；每周5次，持续10周）显著增加了5/6肾切除慢性肾脏病（CKD）大鼠血清肌酐和血尿素氮水平，促进了肾纤维化，并破坏了氧化还原平衡[6]。Hippuric acid（150mg/kg/天；口服；7天）显著降低了DSS诱导的结肠炎小鼠的疾病活动指数（DAI）评分、结肠缩短和组织学炎症评分，增加了结肠长度，并减轻了结肠的组织病理学损伤[7]。

实验参考方法 Experimental Reference Method

Cell experiment [1]:

Cell lines

RAW 264.7 cells and primary mouse bone marrow cells

Preparation Method

Non adherent bone marrow cells from 4‐week‐old female C57BL/J mice were isolated. Bone marrow cells were flushed from femurs and then cultured in T175 Flasks for 2 days to let stromal cells attach. Two days later, non adherent cells were collected and cultured in appropriate plates with appropriate cell densities. These cells are considered as hematopoietic osteoclast progenitor cells. Conditional serum for treatment of cells was taken from female rats either fed 10% BB supplemental diet or standard rodent casein diet for 4 weeks. RAW 264.7 cells and primary mouse bone marrow cells were cultured in α‐Minimum Essential Medium supplemented with 10% fetal bovine serum, penicillin (100units/ml), streptomycin (100µg/ml), and glutamine (4mM). Cells were seeded in 96‐, 12‐, or 6‐well cell culture plates at appropriate density of cells per well for morphology, RNA, and protein expression experiments. At 85% confluence, cells in 96‐well plates were treated with 2.5% rat serum (7.5% FBS) in the presence of 50ng/ml of soluble RANKL for osteoclastic cell morphologic study. RAW264.7 cells or nonadherent bone marrow cells were cultured in 96‐well plates (2×104 cells/well) in the presence or absence of 50ng/ml of RANKL. Cells were treated with 60µg/dL Hippuric acid. After 4 days for RAW264.7 cell cultures and 5 days for bone marrow cell cultures, the cells were fixed with 4% paraformaldehyde and stained for tartrate‐resistant acid phosphatase (TRAPase) activity using a TRAPase Staining Kit. TRAP‐positive cells containing >3 nuclei in each well were counted as osteoclasts under an epifluorescent microscope. For osteoclast resorption activity assay, cells in the culture plates were fixed using 2.5% glutaraldehyde with or without Von Kossa staining. The areas of hydroxyapatite resorption were observed by light microscopy and analyzed using the Image J software. Cell viability was measured by MTT assay.

Reaction Conditions

60µg/dL; 4-5days

Applications

Treatment of RAW 264.7 cells and primary mouse bone marrow cells with Hippuric acid significantly inhibited osteoclastogenesis and osteoclast resorptive activity.
Animal experiment [2]:

Animal models

Male Sprague Dawley rats

Preparation Method

Male Sprague Dawley rats at the age of 7 weeks were housed in a pathogen-free environment. The environment was that with a humidity of 50-70%, temperature of 22-24℃, and the day and night cycle was 12/12h. These rats were given a normal laboratory diet with ad libitum access to water. After 1 week of adaptation, fifty rats were subjected to either sham surgery (kidney exposure operation only) or 5/6NX surgery. The 5/6NX model commonly used to simulate typical CKD symptoms and study PUBT-promoted renal fibrosis. Two weeks after surgery (experimental week 1), excluding the rats that died during the operation, rats in the sham group (n=9) were treated with vehicle (0.5% DMSO), and 5/6NX rats were randomized into two groups (n=9 each) and treated as follows: (1) a 5/6NX group, 0.5% DMSO; (2) a 5/6NX + Hippuric acid group, 100mg/kg Hippuric acid. All treatments were administered intraperitoneally, five times per week for 10 weeks. Rats serum creatinine (SCr) and blood urea nitrogen (BUN) contents were evaluated using a BS-420 automated biochemical analyzer. Kidney samples were fixed for histological and immunohistochemical analyses. Total intracellular ROS and H2O2 concentrations were determined using commercial ROS and H2O2 assay kits.

Dosage form

100mg/kg; intraperitoneal injection; five times per week for 10 weeks

Applications

Hippuric acid significantly increased serum creatinine and blood urea nitrogen levels, promoted renal fibrosis, and disrupted redox homeostasis in a 5/6 nephrectomy rat model of chronic kidney disease.

References:
[1] Zhao H, Lazarenko OP, Chen JR. Hippuric acid and 3-(3-hydroxyphenyl) propionic acid inhibit murine osteoclastogenesis through RANKL-RANK independent pathway. J Cell Physiol. 2020;235(1):599-610.
[2] Sun B, Wang X, Liu X, et al. Hippuric Acid Promotes Renal Fibrosis by Disrupting Redox Homeostasis via Facilitation of NRF2-KEAP1-CUL3 Interactions in Chronic Kidney Disease. Antioxidants (Basel). 2020;9(9):783.

产品文档 Product Documents

Purity:>99.00%

化学性质Chemical Properties

CAS 号
495-69-2
同义词
马尿酸,2-Benzamidoacetic acid
SMILES
O=C(O)CNC(C1=CC=CC=C1)=O
分子式
C9H9NO3
分子量
179.17 g/mol
溶解性
DMSO : ≥ 100 mg/mL (558.13 mM)
保存条件
Store at -20°C
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
为了提高溶解度，请将管子加热至 37°C，然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备 RT，或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

g/mol